Adult Translational Cancer Research

V Foundation
LOI Due Date
Application Due Date
abstract and NIH biosketch to Sarah Laye by 3/8/2023
Brief Description

PURPOSE OF AWARD: This Request for Applications (RFA) is specifically for adult cancer research through the Translational grant mechanism. Applicants may propose adult cancer research that moves a novel strategy from the laboratory into a human clinical trial or uses specimens from a clinical trial to develop biomarkers or mechanisms. The research should apply in some direct way to human beings within the time frame of less than 3 years from the end of the grant. If biomarker research is undertaken, a validation set or independent clinical trial is essential. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new clinical trial.

SPECIAL FOCUS AREA: This RFA is specifically for adult cancer research that falls into preclinical/translational research as described above. This year, we have special interest and funding for therapeutic resistance and welcome research projects in this area. Please note that research areas not included in this scope are epidemiology, behavioral science, and health services research.

GRANT SPECIFICS: The grant amount is $800,000, paid in four annual installments, and allows for 10% indirect costs (not to exceed $80,000 within the award).

WHO MAY APPLY? Each invited institution may submit one nominee to apply